BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17920663)

  • 1. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.
    Nomura S; Shouzu A; Omoto S; Inami N; Tanaka A; Nanba M; Shouda Y; Takahashi N; Kimura Y; Iwasaka T
    Thromb Res; 2008; 122(1):39-45. PubMed ID: 17920663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients.
    Nomura S; Inami N; Shouzu A; Omoto S; Kimura Y; Takahashi N; Tanaka A; Urase F; Maeda Y; Ohtani H; Iwasaka T
    Platelets; 2009 Feb; 20(1):16-22. PubMed ID: 19172517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients.
    Nomura S; Shouzu A; Omoto S; Inami N; Shimazu T; Satoh D; Kajiura T; Yamada K; Urase F; Maeda Y; Iwasaka T
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):440-7. PubMed ID: 19525846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pitavastatin on adiponectin in patients with hyperlipidemia.
    Inami N; Nomura S; Shouzu A; Omoto S; Kimura Y; Takahashi N; Tanaka A; Nanba M; Shouda Y; Iwasaka T
    Pathophysiol Haemost Thromb; 2007; 36(1):1-8. PubMed ID: 18332608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients.
    Nomura S; Taniura T; Shouzu A; Omoto S; Inami N; Fujita S; Tamaki T; Yokoi T; Shimizu T; Ito T
    Int J Gen Med; 2012; 5():535-40. PubMed ID: 22807641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus.
    Nomura S; Kanazawa S; Fukuhara S
    J Diabetes Complications; 2003; 17(3):153-9. PubMed ID: 12738400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes.
    Huang CH; Huang YY; Hsu BR
    J Diabetes Investig; 2016 Sep; 7(5):769-76. PubMed ID: 27181110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing plasma levels of soluble cell adhesion molecules (sE-Selectin, sP-Selectin and sICAM-1) in overweight adults with combined hyperlipidemia.
    Kvasnicka T; Kvasnicka J; Ceska R; Grauová B; Vrablík M
    Sb Lek; 2001; 102(4):473-7. PubMed ID: 12448198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forty-eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas.
    Zhou X; Wu L; Chen Y; Xiao H; Huang X; Li Y; Xiao H; Cao X
    J Diabetes Investig; 2021 Jul; 12(7):1278-1286. PubMed ID: 33289308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase of inflammatory state in overweight adults with combined hyperlipidemia.
    Kvasnicka T; Kvasnicka J; Ceska R; Vrablik M
    Nutr Metab Cardiovasc Dis; 2003 Aug; 13(4):227-31. PubMed ID: 14650355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
    Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
    Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study).
    Nomura S; Taniura T; Shouzu A; Omoto S; Suzuki M; Okuda Y; Ito T
    Vasc Health Risk Manag; 2018; 14():225-232. PubMed ID: 30271161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia: A Randomized, Open-labeled, Multicentered, Phase IV Study.
    Lee HY; Han KH; Chung WB; Her SH; Park TH; Rha SW; Choi SY; Jung KT; Park JS; Kim PJ; Lee JM; Jeong MH; Shin ES; Gwon HC; Han KR; Chae JK; Kim WS; Choi DJ; Hong BK; Choi SW; Chung N
    Clin Ther; 2020 Oct; 42(10):2036-2048. PubMed ID: 32921501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin.
    Arnaboldi L; Corsini A
    Atheroscler Suppl; 2015 Jan; 16():1-27. PubMed ID: 25575403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.
    Nomura S; Takahashi N; Inami N; Kajiura T; Yamada K; Nakamori H; Tsuda N
    Atherosclerosis; 2004 Jun; 174(2):329-35. PubMed ID: 15136063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients.
    Shimazu T; Inami N; Satoh D; Kajiura T; Yamada K; Iwasaka T; Nomura S
    J Thromb Thrombolysis; 2009 Nov; 28(4):429-35. PubMed ID: 19137265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy of pitavastatin and colestimide in Japanese patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome.
    Kato T; Inagaki K; Sawai Y; Kanayama H; Katada N; Itoh M
    Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):554-8. PubMed ID: 21472664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J; Gosho M; Budinski D; Hounslow N
    Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.